utational activation of KRAS is the critical genetic driver of pancreatic ductal adenocarcinoma (PDAC) initiation and progression 1 and is essential for maintenance of PDAC tumorigenic growth 2, 3 . Given that 95% of PDAC harbor KRAS driver mutations, the National Cancer Institute has identified the development of anti-KRAS therapies as one of four priorities for pancreatic cancer research 4, 5 . There are at least five major directions of current anti-KRAS drug discovery [6] [7] [8] . One promising strategy aims to target mechanisms that mediate the KRAS-dependent metabolic functions that support the increased energy needs of PDAC 9, 10 . One such function is macroautophagy (autophagy, or 'self-eating'), a lysosome-mediated process whereby cells degrade organelles and macromolecules and recycle cellular waste 11 . The resulting breakdown products are used as bioenergetic intermediates to sustain metabolic requirements. Because autophagy both is upregulated in KRASmutant PDAC 12 and is critical for tumorigenic growth 13 the autophagy inhibitor hydroxychloroquine is under clinical evaluation for PDAC treatment (clinical trials NCT01273805, NCT01506973 and NCT03344172). Hydroxychloroquine has shown limited activity as a monotherapy 14, 15 ; but has shown promise in combination with preoperative gemcitabine plus nab-paclitaxel (NCT01978184) 16 . It has been assumed, albeit not demonstrated, that KRAS drives the high basal levels of autophagy seen in KRAS-mutant PDAC. Therefore, to identify better therapeutic strategies, we first examined mechanisms whereby mutant KRAS contributes to autophagy in PDAC. We demonstrate that acute suppression of KRAS further elevated rather than decreased the already high basal levels of autophagy in a panel of human and mouse PDAC cell lines. BRAF inhibition in BRAF-mutant melanoma also increases autophagy 17, 18 . Additionally, we recently showed that the rare subpopulation (<10%) of mouse PDAC cells that survive chronic ablation of Kras G12D become more dependent on autophagy and mitochondrial respiration 19 . In this study, we evaluated PDAC cells after acute ablation of mutant KRAS and determined that ERK inhibition phenocopied KRAS suppression and caused increased autophagy. We observed that autophagy was elevated at multiple levels, including increased autophagosome flux, phosphorylation and activation of AMPK and Beclin-1, downregulation of the mTOR pathway, and . Furthermore, we demonstrate that either KRAS suppression or ERK inhibition decreased both glycolytic and mitochondrial functions. We speculated that ERK inhibition might thus enhance PDAC dependence on autophagy, in part by impairing other KRAS-or ERK-driven metabolic processes. Accordingly, we found that the autophagy inhibitor chloroquine and genetic or pharmacologic inhibition of specific autophagy regulators synergistically enhanced the ability of ERK inhibitors to mediate antitumor activity in KRAS-driven PDAC. We conclude that combinations of pharmacologic inhibitors that concurrently block both ERK MAPK and autophagic processes that are upregulated in response to ERK inhibition may be effective treatments for PDAC.
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utational activation of KRAS is the critical genetic driver of pancreatic ductal adenocarcinoma (PDAC) initiation and progression 1 and is essential for maintenance of PDAC tumorigenic growth 2, 3 . Given that 95% of PDAC harbor KRAS driver mutations, the National Cancer Institute has identified the development of anti-KRAS therapies as one of four priorities for pancreatic cancer research 4, 5 . There are at least five major directions of current anti-KRAS drug discovery [6] [7] [8] . One promising strategy aims to target mechanisms that mediate the KRAS-dependent metabolic functions that support the increased energy needs of PDAC 9, 10 . One such function is macroautophagy (autophagy, or 'self-eating'), a lysosome-mediated process whereby cells degrade organelles and macromolecules and recycle cellular waste 11 . The resulting breakdown products are used as bioenergetic intermediates to sustain metabolic requirements. Because autophagy both is upregulated in KRASmutant PDAC 12 and is critical for tumorigenic growth 13 the autophagy inhibitor hydroxychloroquine is under clinical evaluation for PDAC treatment (clinical trials NCT01273805, NCT01506973 and NCT03344172) . Hydroxychloroquine has shown limited activity as a monotherapy 14, 15 ; but has shown promise in combination with preoperative gemcitabine plus nab-paclitaxel (NCT01978184) 16 . It has been assumed, albeit not demonstrated, that KRAS drives the high basal levels of autophagy seen in KRAS-mutant PDAC. Therefore, to identify better therapeutic strategies, we first examined mechanisms whereby mutant KRAS contributes to autophagy in PDAC. We demonstrate that acute suppression of KRAS further elevated rather than decreased the already high basal levels of autophagy in a panel of human and mouse PDAC cell lines. BRAF inhibition in BRAF-mutant melanoma also increases autophagy 17, 18 . Additionally, we recently showed that the rare subpopulation (<10%) of mouse PDAC cells that survive chronic ablation of Kras G12D become more dependent on autophagy and mitochondrial respiration 19 . In this study, we evaluated PDAC cells after acute ablation of mutant KRAS and determined that ERK inhibition phenocopied KRAS suppression and caused increased autophagy. We observed that autophagy was elevated at multiple levels, including increased autophagosome flux, phosphorylation and activation of AMPK and Beclin-1, downregulation of the mTOR pathway, and . Acute KRAS suppression using a previously validated siRNA oligo 23 increased autophagic flux by two-to ten-fold in six of seven KRAS-mutant human PDAC cell lines (Fig. 1a, b and Supplementary Fig. 1a ). Recently, compounds with high selectivity and potency for KRAS G12C have been developed 24 . Treatment of KRAS G12C-mutant MIA PaCa-2 cells with the RAS inhibitor ARS-1620 led to a similar increase in autophagic flux ( Fig. 1c and Supplementary Fig. 1b ). Second, we examined autophagosome assembly by exogenously expressing EGFP-LC3B and monitoring autophagosome-associated punctae formation (Extended Data Fig. 1b,c) . These results indicate that the increased punctae observed upon KRAS suppression were due to increased autophagic flux, not simply to changes in steady state. As a third complementary method, we performed immunoblotting to monitor conversion of endogenous LC3B-I to the lipidated, autophagosome-associated form, LC3B-II. Our results are in agreement with the fact that this method can be confounded in tumorderived cell lines with basally high levels of LC3B-II 21 . However, we observed that siRNA-induced KRAS suppression increased the ratio of LC3B-II to LC3B-I, and that this increased ratio was maintained when autophagosome degradation was inhibited with bafilomycin A1 (Fig. 1d) . Thus, suppression of KRAS increased autophagic flux in KRAS-mutant PDAC cell lines, as demonstrated by increases in autophagosome formation, lysosomal fusion and autophagosomeassociated LC3B-II.
We next extended these results to a well-characterized doxycycline-inducible Kras G12D-driven mouse model of PDAC (iKRAS) that has been used to implicate KRAS as a critical driver of metabolic signaling in PDAC 3 . In three tumor cell lines established from this model, we observed both a 7-to 20-fold increase in the autophagic index upon acute (24 h ) suppression of Kras G12D by doxycycline withdrawal (-Dox, Fig. 1e ; Supplementary Fig. 1c ) and an increase in the ratio of LC3B-II to LC3B-I as visualized by immunoblotting (Fig. 1f) . Thus, in both human and mouse PDAC, suppression of mutant KRAS led to increased, rather than decreased, autophagy.
AMPK and Beclin-1 are key drivers of early-stage autophagy initiation and phagophore assembly 25 . Having established that KRAS silencing induces autophagic flux, we next tested whether upstream autophagic signaling could be influenced by perturbations in KRAS levels. Consistent with increased rather than decreased autophagy, we found that shRNA-mediated KRAS suppression increased the activating phosphorylation of AMPK and either activated or increased the level of total Beclin-1 in a panel of KRAS-mutant PDAC cell lines ( Fig. 1g ) and iKRAS cells ( Supplementary Fig. 1d ). Additionally, gene set variation analysis (GSVA) 26 of RNA sequencing (RNA-seq) data from a panel of ten KRAS-mutant PDAC cell lines revealed that transient shRNA suppression of KRAS in nine of ten lines was associated with increased transcription of genes encoding proteins that drive autophagy (Supplementary Table 1 and Supplementary Fig. 1e ). In contrast to the increased autophagic flux and AMPK activation observed in KRAS-mutant PDAC lines, KRAS suppression led to neither of these in the KRAS wild-type PDAC cell line BxPC-3, which harbors mutationally activated BRAF rather than mutant KRAS (Fig. 1h,j) . Furthermore, KRAS G12V transformation of immortalized HPNE human pancreatic ductderived cells 27 decreased autophagic flux ( Supplementary Fig. 1f ,h). Similarly, KRAS G12V transformation of rat intestinal epithelial cells (RIE-1) decreased autophagic flux ( Supplementary Fig. 1i ,k). Thus, upon using multiple assays to monitor autophagy under different conditions in two different pancreatic cell models, we conclude that KRAS ablation leads to a further upregulation of autophagy, supporting its role as a key survival mechanism in PDAC.
ERK inhibition elevates autophagic flux.
We recently determined that the ERK1/ERK2 mitogen-activated protein kinases have a critical role in the in vitro and in vivo growth of KRAS-mutant PDAC 23 . Fig. 1 | KRAS suppression increases autophagic flux in KRAS-mutant PDAC cell lines. a, PDAC cell lines were stably infected with a lentiviral vector encoding mCherry-EGFP-LC3B and then transiently transfected with siRNA targeting KRAS (KRAS) or a mismatch control oligo (MM) (72 h). To quantify autophagic flux, the area ratios of mCherry + punctae to EGFP + punctae (autophagic index) were determined. Mean autophagic index is plotted, with each individual data point representing one field containing at least ten analyzed cells. Data for HPAC, PANC-1, Pa01C and Pa14C represent two independent experiments; data for HPAF-II, Pa04C and Pa16C cells represent one independent experiment. b, Representative images of cells described and quantified in a, which visualize autophagosomes (EGFP + and mCherry + ) and autophagolysosomes (mCherry + only). Scale bar, 20 μm. c, MIA PaCa-2 cells expressing mCherry-EGFP-LC3B were transfected with siRNA targeting KRAS as described in a or treated with ARS-1620 (10 μM, 24 h) , and the mean autophagic index was determined. Data are representative of three independent experiments. d, PDAC cell lines were transiently transfected with siRNA as described in a and treated with bafilomycin A1 (Baf, 200 nM, 2 h) to assess flux. Immunoblot analyses of cell lysates were done to determine the levels of LC3B, KRAS and vinculin (control for total protein) and are representative of three independent experiments. e, Three cell lines derived from the iKRAS doxycycline-inducible PDAC mouse model were stably infected with a lentiviral vector encoding mCherry-EGFP-LC3B. Doxycycline was removed (-Dox) from the medium for 24 h, and mean autophagic flux was assessed as described in a. Data are representative of two independent experiments. f, iKRAS cells were deprived of doxycycline for 24 h to silence Kras G12D expression and treated with Baf (200 nM, 2 h) to assess autophagic flux. Immunoblots were performed as in d and are representative of three independent experiments. g, PDAC cell lines were stably infected with lentiviral vectors encoding shRNA targeting KRAS or a nonspecific control (96 h). Immunoblots were done to determine the levels of phosphorylated AMPKα (pAMPKα), total AMPKα, phosphorylated Beclin-1 (pBeclin-1), total Beclin-1, KRAS and vinculin and are representative of three independent experiments. h, BxPC-3 cells were processed and imaged as described in a. Mean autophagic index of five independent experiments is plotted. i, Representative images of BxPC-3 cells as described in h (scale bar, 20 μm), representative of five independent experiments. j, BxPC-3 cells were transiently transfected with siRNA as in a and immunoblotted to determine the levels of pAMPKα, KRAS and β-actin (control for total cellular protein); immunoblots are representative of three independent experiments. All P values shown are from unpaired, two-sided t-test. Error bars represent s.e.m.
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To determine whether loss of this key KRAS effector pathway is likewise important for KRAS suppression-induced autophagy, we treated PDAC cell lines with the ERK1/ERK2-selective inhibitor SCH772984 (ERKi) 28 (Extended Data Fig. 1a ), an analog of the clinical candidate MK-8353/SCH900353 (ref. 29 ). We found that shortterm (24 h) ERKi treatment stimulated a 3-to 30-fold increase in autophagy in eight of eight human PDAC cell lines stably expressing the mCherry-EGFP-LC3B autophagy reporter (Fig. 2a,b) . In a complementary approach, we also observed a 2-to 12-fold increase in EGFP + autophagosomes upon ERKi treatment of human PDAC cells stably expressing EGFP-LC3B (Extended Data Fig. 2a,b) .
Confirming increased autophagic flux, we observed an increased ratio of LC3B-II to LC3B-I in ERKi-treated cells compared to vehicle-treated controls both basally and in the presence of bafilomycin A1 to inhibit flux (Fig. 2c ). Extending these results to the iKRAS model, we observed that ERK inhibition also phenocopied Kras G12D silencing in three of three mouse iKRAS PDAC lines, causing extensive 10-to 30-fold increases in autophagic flux (Fig. 2d,e) .
To confirm the ability of ERK inhibition to phenocopy KRAS suppression and to induce increased autophagic signaling before autophagosome formation, we also examined activation of AMPK and Beclin-1 upon ERKi treatment. As we observed upon genetic a, PDAC cell lines were transduced to stably express mCherry-EGFP-LC3B and then treated with the ERK1/ERK2 inhibitor, SCH772984 (ERKi, 1 μM) or DMSO for 24 h. Autophagic index indicates the ratio of the areas of mCherry + punctae to EGFP + punctae. Mean autophagic index is plotted, with each individual data point representing one field containing at least ten analyzed cells. Data for HPAC, PANC-1 and Pa14C cells are representative of three independent experiments; two independent experiments were performed for Pa01C and Pa16C cells; and one was performed for CFPAC-1, SW1990 and Pa04C cells. b, Representative images of cells described and quantified in a; scale bar, 20 μm. c, PDAC cell lines were treated with DMSO or SCH772984 (ERKi, 1 μM, 24 h); Baf was added (200 nM, 2 h) to assess flux. Immunoblot analyses of cell lysates were done to determine the levels of LC3B and vinculin, and are representative of three independent experiments. d, Three cell lines derived from the iKRAS doxycycline-inducible PDAC mouse model were stably infected with a retroviral vector encoding mCherry-EGFP-LC3B. Cells were treated with SCH772984 (ERKi, 1 μM, 24 h) and mean autophagic flux was assessed as described in a. Data are representative of two independent experiments. e, Representative images of cells described and quantified in d; scale bar, 20 μm. f, PDAC cell lines were treated with DMSO or SCH772984 (ERKi, 250 nM, 500 nM or 1 μM) for 24 h. Immunoblot analyses of cell lysates were done to determine the levels of pAMPKα, total AMPKα, pBeclin-1, total Beclin-1 and β-actin, and are representative of three independent experiments. g, BxPC-3 cells were prepared as described in a. Mean autophagic index of five independent experiments is plotted. h, Representative images of cells quantified in g; scale bar, 20 μm. i, BxPC-3 cells treated as described in g. Immunoblot analyses of cell lysates were done to determine the levels of pAMPKα, total AMPKα, pBeclin-1, total Beclin-1 and β-actin, and are representative of three independent experiments. All P values shown are from unpaired, two-sided t-test. Error bars represent s.e.m.
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NAtuRE MEDiCiNE suppression of KRAS, ERK inhibition also stimulated increased AMPK and Beclin-1 phosphorylation in human PDAC cells (Fig. 2f) . Although PRKAA2 and BECN1 transcription was elevated in some cell lines (Extended Data Fig. 2c ), increased levels of phosphorylated Beclin-1 were observed within 1 h of ERKi treatment (Extended Data Fig. 2d ), supporting the idea that KRAS regulates autophagy in PDAC through the ERK MAPK cascade. Finally, BxPC-3 cells exhibited elevated autophagy 12 despite lacking mutant KRAS, owing to upregulated ERK signaling and ERK-dependent growth 30, 31 downstream of mutant BRAF. Again, consistent with the critical role of ERK signaling in regulating autophagy, we found that ERKi treatment of BxPC-3 cells also increased autophagic flux (Fig. 2g,i) .
ERK inhibition deregulates metabolic activities. We next addressed the mechanistic basis of the ERKi-induced increase in autophagic flux. First, we performed reverse-phase protein microarray (RPPA) analyses 32 on a panel of 12 human PDAC cell lines treated with ERKi or vehicle (DMSO) for 1 or 24 h (Fig. 3a , Supplementary Fig. 2a and Supplementary Tables 2-4) . Comparison of the mean values of all proteins assayed revealed decreases in wellvalidated markers of ERK inhibition including reductions in phosphorylated and activated ERK1/ERK2, in phosphorylation of the ERK substrate RSK, and in total MYC protein, an ERK-regulated substrate (Extended Data Fig. 3a) . We have previously reported that acute ERK inhibition can lead to a limited degree of apoptosis 23 , and indeed we observed upregulation of apoptotic mediators including BIM, PUMA and cleaved PARP and caspase 7 after 24 h of ERKi treatment (Extended Data Fig. 3b) . Notably, we further validated that ERK inhibition stimulated AMPK activation, and additionally observed decreased mTORC1 signaling (Fig. 3a,b and Supplementary Fig. 2b ). Both signaling changes are prominent mechanisms that can promote autophagy (Extended Data Fig. 1a) upon ERKi treatment 33 . Correlation analysis of the RPPA data confirmed that levels of phosphorylated AMPK were negatively correlated with markers of ERK inhibition, whereas the decreases in mTOR pathway components were positively correlated with those same markers (Extended Data Fig. 3c ).
We next analyzed polar metabolite levels using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based differential metabolomics on a panel of ERKi-treated PDAC cell lines. Consistent with the increased AMPK activation identified by RPPA, our metabolomics analyses demonstrated that a subset of PDAC cell lines also had increased levels of AMP, as well as increased levels of the AMP precursor, IMP, and/or the AMP degradation product, hypoxanthine, upon ERKi treatment ( Fig. 3c ; Extended Data Fig. 3d ), suggesting that ERKi induces increased autophagic flux in part by altering nucleotide metabolism. Furthermore, we performed RNA-seq analysis on a panel of seven human PDAC cell lines treated with ERK inhibitor over 24 h. Implementing GSVA to determine the variation of different metabolic pathway activities over time in a nonsupervised manner, we identified ERKi-mediated increased expression of autophagy-related and lysosomal genes (Fig. 3d,e, Supplementary Fig. 2c and Supplementary Table 1) . Finally, we used quantitative PCR to verify dose-dependent increases in transcripts of autophagy-related genes, in particular those that encode autophagy cargo receptors, upon ERKi treatment (Extended Data Fig. 3e ). Thus, ERK inhibition increases autophagy at the levels of autophagic signaling, nucleotide metabolism and gene transcription.
In contrast to upregulation of gene transcription supporting autophagy, our RNA-seq analyses also identified ERK inhibition-induced reductions in transcripts of genes supporting glycolysis (Fig. 3f, Supplementary Fig. 3a and Supplementary Table 1 ). These transcriptomic changes were phenocopied by KRAS knockdown (Supplementary Fig. 3b ). To verify that these changes led to reduced glycolytic activity, we performed metabolic flux analyses by [ 13 C]glucose LC-MS and NMR. We genetically silenced KRAS using a validated siRNA construct or treated cells with ERKi before incubating cells with [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose. We found that KRAS suppression and ERK inhibition decreased both glucose uptake and accumulation of cellular and secreted lactate ( Supplementary Fig. 3c,f) . Accordingly, we observed a marked decrease in key glycolytic intermediates in a panel of seven KRAS-mutant PDAC cell lines upon ERKi treatment (Extended Data Fig. 4a ). Our previous analyses in the iKRAS PDAC mouse model demonstrated that mutationally activated KRAS drives glycolytic activity and that suppression of Kras G12D decreases it 3 . Consistent with those results, we conclude that mutationally activated KRAS regulates glycolytic activity that is effectively suppressed after ERK inhibition in human PDAC lines. We hypothesized that this ERK inhibition-induced reduction in glycolytic activity contributes to the ERK inhibitor-mediated increase in autophagic flux that we observed. Accordingly, we found that when glucose was withdrawn from the growth medium of PDAC cells, autophagic flux increased, albeit to a lesser degree than we observed with ERK inhibition (Extended Data Fig. 4b ). Hence, we conclude that ERK inhibitor treatment increases autophagic flux through both direct signaling mechanisms and an indirect reduction in glycolysis. Three independent experiments were prepared, and RPPA analysis was performed. RPPA expression data for 1 h of SCH772984 treatment were standardized to no-treatment samples, and 24 h SCH772984-treatment samples were standardized to 24 h DMSO-treated samples. Data were log 2 transformed, and medians of three independent experiments are represented in the heatmap. Only proteins with statistically significant (P < 0.05, FDR corrected, Wilcoxon test) changes at 1 or 24 h are shown. Samples and proteins were arranged via hierarchical clustering. b, Mean comparisons of autophagy-and mTOR pathway-related proteins from RPPA data in which all 12 cell lines (shown in a) are averaged based on treatment condition and treated as biological replicates. P values are from unpaired, two-sided, t-test (phosphorylated mTOR (s2448)) or Wilcoxon test (all other proteins) comparing the mean of cells treated with SCH772984 (ERKi, 1 μM, 24 h) to vehicle control (DMSO) are shown; error bars denote s.e.m. c, Normalized mean-peak intensities for IMP, AMP and hypoxanthine identified from triplicate LC-MS/MS experiments. The average metabolite concentrations from SCH772984-treated (ERKi, 1 μM) samples are normalized to DMSO controls; P values are from two-sided, unpaired t-test; error bars denote s.e.m. Mean of three independent experiments is plotted. d, A panel of seven PDAC cell lines (HPAC, PANC-1, HPAF-II, SW1990, Pa01C, Pa04C and Pa14C) were treated with SCH772984 (1 µM) for 1, 4, 12 or 24 h. Cells were collected, and RNA-seq analysis was performed. GSVA was completed to estimate the variation of different metabolic pathway activities over time in a nonsupervised manner. Each of the seven cell lines was treated as a biological replicate. Shown are the GSVA scores for a gene set composed of autophagy-related genes. Significance was determined based on a repeated measures ANOVA. Box plot components include minimum, 25th percentile, median, 75th percentile and maximum. e, Samples were prepared and analyzed as described in d. Shown are the GSVA scores for a gene set composed of lysosomal membrane proteins and hydrolases. Significance was determined as in d. f, Samples were prepared and analyzed as described in d. Shown are the GSVA scores for a gene set composed of glycolysis-related genes. Significance was determined as in d. g, Samples were prepared and analyzed as described in d. Shown are the GSVA scores for a gene set composed on mitochondrial biogenesis-related genes. Significance was determined as in d.
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ERK inhibition impairs mitochondrial activity. Our RNA-seq data showed that ERKi treatment led to decreased transcription of mitochondrial biogenesis-related genes (Fig. 3g , Supplementary  Fig. 3g and Supplementary Table 1), and this was phenocopied by KRAS suppression (Supplementary Fig. 3h) . Our previous studies have demonstrated that the rare subpopulation (<10%) of mouse PDAC cells that can survive long-term Kras G12D ablation becomes more dependent on mitochondrial respiration 19 . Therefore, our finding that acute KRAS suppression or ERK inhibition decreased the transcription of mitochondria-associated genes in the bulk populations subjected to these acute treatments was somewhat unexpected to us. We first assessed the functional consequences of short-term KRAS suppression and ERK inhibition on mitochondrial morphology and activity in KRAS-mutant PDAC cell lines. We found that ERKi treatment reduced mitochondrial mass ( Fig. 4a and Supplementary Fig. 3i ). Accordingly, we observed an increase in mitophagic flux upon ERK inhibition, as well as increased levels of total PINK1 (Extended Data Fig. 5a,c) . Thus, together with 34, 35 . Notably, we found that ERK inhibitor treatment induced mitochondrial fusion in PDAC cell lines within 1 h (Fig. 4b,c) . This was associated with decreased phosphorylation of DRP1 (Fig. 4d) , a mediator of mitochondrial fission and a validated ERK substrate 34 . Mitochondrial fusion and decreased DRP1 phosphorylation were maintained after 24 h of ERKi treatment (Fig. 4e,f) . At this time point, we also began to observe a decrease in total DRP1 protein ( Fig. 4g) , consistent with our observation that mitochondria-related gene transcription decreases after 24 h. The increased mitochondrial fusion upon ERK inhibition was phenocopied by short-term KRAS suppression in human PDAC lines (Extended Data Fig. 5d ,e) and by Kras G12D suppression (-Dox) in iKRAS mouse PDAC lines (Fig. 4h) . Overall, both ERK inhibition and KRAS suppression led to a marked rearrangement of the mitochondrial network, favoring robust fusion over the fragmented nature typically observed in PDAC.
Mitochondrial fusion has been associated with increased mitochondrial activity 35 . Indeed, the increased fusion we observed was accompanied by increased mitochondrial potential both in human PDAC cell lines (Fig. 4i, j and Supplementary Fig. 3j, k) and in the iKRAS model (Extended Data Fig. 6a and Supplementary Fig. 3l ). However, we observed no change in oxygen consumption rate in cells treated with ERKi for 1.5 h (Fig. 4k) , a timescale at which we observed robust mitochondrial fusion. Furthermore, when human PDAC cell lines were treated with ERKi for 24 h, the basal oxygen consumption rate, as well as ATP production, was either decreased or unchanged (Fig. 4l) . A similar lack of effect on oxygen consumption was observed after KRAS suppression in human PDAC cells, as well upon turning off Kras G12D expression in iKRAS mouse PDAC lines (Extended Data Fig. 6b ,c). In agreement with the increase in mitochondrial potential, a small increase in spare mitochondrial capacity was observed upon Kras suppression in the iKRAS model (Extended Data Fig. 6b ), as well as upon ERKi treatment in a subset of human PDAC cell lines (Fig. 4l) . However, because we did not observe concomitant increases in oxygen consumption or ATP production, we conclude that this increased potential was not used for energy production.
Finally, we applied [ 13 C]glucose LC-MS metabolic flux analysis to monitor the formation of 13 C-labeled glutamate, a measure of flow through the tricarboxylic acid (TCA) cycle 36, 37 , which sustains mitochondrial metabolism. Incorporation of different numbers of 13 C atoms from [1, [6] [7] [8] [9] [10] [11] [12] [13] C]glucose into glutamate reflects in part the number of turns that the TCA cycle has undergone. Incorporation of one labeled 13 C carbon within glutamate indicates the first half turn after glycolysis, as shown by the increase from the monoisotopic isotopologue (M+0) to the M+1 isotopologue. The incorporation of two labeled 13 C carbons (M+2 isotopologue) indicates another consecutive turn. Upon fitting isotopologue distributions of labeled glutamate to a one-phase exponential model, we observed decreases in the rate of formation (K) of M+1 and M+2 glutamate upon KRAS suppression by siRNA ( Supplementary Fig. 3m ). ERKi treatment had similar effects ( Supplementary Fig. 3n ). These results further support the notion that glucose-derived carbon incorporation into the TCA cycle is unchanged or reduced, rather than increased, after perturbation of the KRAS-ERK pathway.
ERK inhibition enhances dependence on autophagy. We speculated that the increase in autophagy that we observed upon inhibiting ERK may produce a greater dependence on the autophagic process in ERKi-treated PDAC cells. If so, concurrent inhibition of ERK and autophagy should be more effective than either alone. Although there are no specific inhibitors of autophagy in the clinic, hydroxychloroquine, a general inhibitor of lysosomal acidification and thus an indirect inhibitor of autophagy, is routinely used. Accordingly, we found that concurrent treatment with SCH772984, the chemically and mechanistically distinct clinical candidate ERK (ulixertinib/BVD-523) 38 , or the MEK inhibitor binimetinib (MEKi) synergistically enhanced chloroquine-mediated growth inhibition on plastic (Fig. 5a ,b, Extended Data Fig. 7a,b and Supplementary  Fig. 4a ). Synergy was observed over a broad range of ERKi or MEKi concentrations, indicated by combination index values of <1 using the Chou-Talalay or BLISS method ( Fig. 5c and Extended Data Fig. 7b,d) . Notably, synergy was observed irrespective of the method used to quantify cellular proliferation, including both metabolism-dependent processing of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Fig. 5a,b and Extended Data Fig. 7a,c) or live cell counting (Extended Data Fig. 7b,d ). Additionally, ERKi treatment alone caused a limited degree of apoptosis that was significantly increased by the combination treatment ( Fig. 5d and Supplementary Fig. 4b,c) . Synergy was also observed when cells pDRP1), total DRP1 and β-actin is representative of three independent experiments. e, Mitochondrial morphologies of PDAC cells treated with SCH772984 (ERKi, 1 µM) for 24 h. Green, Anti-TOMM20; blue, DAPI; scale bar, 20 μm. f, Quantitation of mitochondrial morphologies observed in cells shown in e. Some 50 cells per condition per repetition were blindly scored; data are means of four independent experiments; error bars denote s.e.m. g, PDAC cells were treated with SCH772984 (ERKi, 1 μM) for 24 h. Immunoblot of pDRP1, total DRP1, MYC, phosphorylated RSK (pRSK) and β-actin is representative of three independent experiments. h, Cell lines derived from the iKRAS PDAC mouse model were deprived of doxycycline (Dox) to turn off Kras G12D for 24 h. Representative transmission electron microscopy (TEM) micrographs displaying mitochondrial morphologies in the presence and absence of doxycycline; images are representative of six independent experiments; scale bar, 500 nm. i, Cells were treated as described in a. Quantification of relative mitochondrial potential via labeling with the JC-1 mitochondrial dye. Data are the mean of three independent experiments; P values are from two-sided, unpaired t-test; error bars denote s.d. of median ratios of JC-1 aggregate fluorescence to JC-1 monomer fluorescence. j, Representative histograms from Pa01C and Pa14C cells quantified in i; as a control, the uncoupler CCCP was added to acquired DMSO samples to establish minimum potential. k, OCR response of PDAC cells treated with DMSO or SCH772984 (ERKi, 1 μM) for 1.5 h; shown is mean OCR of three independent experiments; error bars denote s.e.m. of mean OCR across replicates. l, OCR response of PDAC cells treated with DMSO or SCH772984 (ERKi, 1 μM) for 24 h. Data for HPAC and Pa01C lines are the mean of nine independent experiments; data for Pa14C are the mean of eight independent experiments, and data for PANC-1 are the mean of three independent experiments. P values are from two-sided, unpaired t-test, comparing treatment conditions to DMSO, which was normalized to 100 for each measurement; error bars denote s.e.m.
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were grown as matrix-embedded spheroid cultures, as indicated by BLISS scores and combination index values <1 ( Supplementary  Fig. 4d,e) . Furthermore, when the combination was assessed on matrix-embedded human pancreatic subject-derived organoid cultures, synergy between ERKi and chloroquine was maintained (Fig. 5e ,f and Extended Data Fig. 8a,f) .
To extend these in vitro findings to in vivo tumor growth, we evaluated the combination of ERKi and hydroxychloroquine in two heterogeneous KRAS-mutant pancreatic subject-derived tumor xenograft (PDX) models. In both models, whereas ERKi alone had a significant impact on tumor growth, the combination blocked tumor progression and extended survival more effectively (Fig. 5g and Extended Data Fig. 9a,d) . Additionally, tumors harvested from mice treated with the combination of ERKi and hydroxychloroquine were significantly smaller than tumors from mice treated with ERKi alone (Fig. 5h and Extended Data Fig. 9e ). We conclude that concurrent inhibition of ERK1/ERK2 and autophagy suppresses PDAC growth more effectively than inhibition of ERK alone.
Because chloroquine inhibits autophagy indirectly by blocking lysosomal function, we next determined whether genetic or pharmacologic blockade of specific components of autophagy 21 would also synergize with ERK inhibition (Extended Data Fig. 1a) . We first tested synergy using shRNA suppression of two essential autophagy-related genes (ATG5 and ATG7) involved in elongation Percentage cells 
DMSO ERKi
Articles NAtuRE MEDiCiNE of the autophagosome membrane and complete formation of the autophagosome vesicle 39 . Suppression of either ATG5 or ATG7 significantly enhanced ERKi-induced growth suppression in PDAC cell lines (Fig. 6a,d ). Furthermore, whereas hydroxychloroquine is the only clinically tractable autophagy inhibitor so far, other, more specific tool compounds have been developed, including SBI-0206965 (SBI) 40 , MRT68921 (MRT) 41 , and Spautin-1 42 . SBI targets ULK1 and MRT targets ULK1 and ULK2, which are components of the autophagic preinitiation complex that are phosphorylated by active AMPK. Spautin-1 inhibits two ubiquitin-specific peptidases, USP10 and USP13, that regulate ubiquitination of Beclin-1 in Vps34 complexes that initiate autophagosome formation. Like chloroquine, all three additional autophagy inhibitors reduced the proliferation of PDAC cell lines (Fig. 6e and Extended Data Fig. 10a ). As we observed after genetic suppression of ATG5 and ATG7, treatment with all three distinct pharmacologic inhibitors of different components of autophagy also synergistically enhanced ERKi-mediated growth suppression (Fig. 6f,g and Extended Data Fig. 10b,c) . Having established robust synergy between ERK and autophagy inhibition, we hypothesized that KRAS inhibition would likewise synergize autophagy inhibition. Because the KRAS G12C-mutant MIA-PaCa-2 cells are resistant to chloroquine ( Supplementary Fig. 5 ), we treated them with ARS-1620 (RASi) in combination with SBI or MRT. We observed a synergistic enhancement of ARS-1620-induced growth suppression as well as significantly enhanced apoptosis in combination-treated cells (Fig. 6h,i and Extended Data Fig. 10d ).
Discussion
KRAS-mutant PDAC is characterized by multiple metabolic alterations that include increased dependence on glycolysis, glutaminolysis, autophagy and macropinocytosis 3, 43 . Our previous analyses in the iKRAS PDAC mouse model have shown that increased glycolytic activity is driven by KRAS activation of the ERK MAPK cascade and loss of MYC in a Kras-driven mouse model of PDAC 3 . In the present study, we extend this observation to human PDAC cells by showing that KRAS suppression or ERK inhibition causes similar decreases in glycolytic function. Regarding another metabolic process, Bar-Sagi and colleagues have shown that elevated macropinocytosis in human PDAC is also KRAS dependent 43 , although the effector pathways that drive macropinocytosis remain to be elucidated. We and others have observed that human PDAC exhibits high levels of basal autophagy 12, 13, 20 ; herein, we find that acute KRAS suppression increased rather than decreased autophagy. Furthermore, ERK inhibition phenocopied KRAS suppression and also stimulated increased autophagic flux. Further work is needed to determine the order of the direct and indirect signaling events that lead to increased autophagic flux; however, because we have observed rapid MYC loss associated with both KRAS suppression and ERK inhibition in PDAC, it will be important to assess whether MYC can also regulate autophagy in PDAC.
Additionally, we show that impaired mitochondrial function is a third metabolic alteration caused by either KRAS suppression or ERK inhibition. In agreement with previous studies, we observed that KRAS transformation is associated with a highly fragmented mitochondrial matrix and that ERK MAPK inhibition can block mitochondrial fission, leading to increased mitochondrial fusion 34, 35 . However, although increased mitochondrial fusion has been assumed to reflect an increase in oxygen consumption, and our finding of increased mitochondrial potential is consistent with this possibility, to our surprise, we observed a decrease or no change in mitochondrial oxygen consumption or ATP production after either short-term KRAS suppression or ERK inhibition, in both human and mouse PDAC cell lines. We suggest that the decreased glycolytic activity caused by KRAS suppression or ERK inhibition induces a compensatory response to increase mitochondrial activity that cannot be completed, possibly owing in part to ERK inhibition-induced suppression of the expression of genes involved in mitochondrial biogenesis. Our findings may seem at odds with observations from a recent study in which a subpopulation (<10%) of mouse PDAC cells able to survive long-term Kras G12D ablation become more dependent on mitochondrial respiration 19 . However, as these PDAC cells have escaped addiction to mutant Kras, probably through Yap1 activation, our findings support the critical role of mitochondrial function in supporting PDAC growth after acute ablation of ERK MAPK signaling.
The relationship between mitochondrial morphological dynamics and mitochondrial activities is a topic of intense research 44 . We demonstrated that ERK inhibition leads to the subsequent loss of glycolytic inputs into the TCA cycle. Thus we hypothesize that, to compensate, the cells increase mitochondrial fusion to promote efficient mitochondrial activity. Although we did not observe the increased mitochondrial dependence described after long-term KRAS ablation 19 , mitochondria persisted after acute KRAS suppression and ERK inhibition, albeit at a lower level of activity. Autophagy supplies substrates for the TCA cycle in PDAC cells 12 . Therefore, a basis for the synergy we observe between ERK and autophagy inhibition may be the additive loss of multiple TCA cycle inputs, both from glycolysis and from scavenging pathways such as autophagy. 
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At least 11 RAS effector families have been identified so far, and 6 of these have been validated as contributing to KRAS-driven cancer initiation and/or maintenance 5, 6 . Herein, we demonstrate that ERK inhibition alone phenocopies the genetic silencing of KRAS in both human-and mouse-derived pancreatic cancer models, implicating the RAF-MEK-ERK pathway as the major modulator of RASmediated metabolic alterations. Extending these observations, we additionally observed increased autophagic flux after KRAS silencing or inhibition as well as ERK inhibition in both human PDAC cell lines and lines derived from iKRAS PDAC mice. Thus, although inhibition of specific metabolic enzymes (for example, glutaminase) is being pursued to impair the altered metabolic activities in PDAC 10 , and current inhibitors of macropinocytosis are limited by issues of selectivity and potency, our results lead us to conclude that ERK inhibition is an effective pharmacologic approach for blocking metabolic processes driven by mutant KRAS. This block in turn further enhances PDAC addiction to autophagy, and consequently increases sensitivity to treatment with autophagy inhibitors.
Our previous determination that autophagy is elevated in PDAC and that inhibition of autophagy can suppress PDAC tumorigenic growth has prompted clinical evaluation of the autophagy inhibitor hydroxychloroquine for the treatment of PDAC. Ongoing clinical trials have observed limited to no efficacy of hydroxychloroquine as monotherapy 14 . Herein we demonstrate that concurrent treatment with the ERK inhibitor SCH772984, the clinical candidate ERK inhibitor ulixertinib/BVD-523 38 , or the clinical candidate MEK inhibitor binimetinib synergistically enhanced hydroxychloroquine-mediated growth inhibition in both organoid and PDX models of PDAC, preclinical models that provide improved modeling of the drug response in PDAC subjects 45, 46 . Independent of ). Furthermore, in one PDAC subject, the researchers observed a marked response to concurrent treatment with a MEK inhibitor and hydroxychloroquine. In conclusion, taking our findings together with theirs, we propose a therapeutic strategy whereby inhibitors of the RAF-MEK-ERK cascade disrupt KRAS-driven metabolic processes, driving PDAC to become acutely dependent on autophagy, thereby enhancing its vulnerability and responsiveness to hydroxychloroquine-mediated inhibition of autophagy. As ongoing efforts toward more specific autophagy inhibitors are underway, we anticipate that their use will only increase the efficacy of this treatment strategy.
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Retroviral expression and vector infections.
The pBabe-puro retroviral expression vector was used to ectopically express mCherry-EGFP-LC3B (a gift from J. Debnath (University of California at San Francisco); Addgene plasmid 22418; http://n2t.net/addgene:22418; RRID:Addgene_22418) 48 and a panel of hemagglutinin-tagged KRAS mutants in PDAC cell lines. The pCLBW retroviral vector was used to ectopically express Cox8-EGFP-mCherry (a gift from D. Chan (California Institute of Technology); Addgene plasmid 78520; http://n2t.net/ addgene:78520; RRID:Addgene_78520) 49 in PDAC cell lines. To generate retroviral particles, 0.9 × 10 6 HEK293T cells were plated and incubated overnight. DNA transfection of HEK293T cells was achieved using the Fugene6 protocol. Vector DNA (5 μg) and PCL10A DNA (5 μg) were combined in 400 μl Optimem. Fugene6 (24 μl) was added and the mixture was incubated for 20 min at room temperature before being added dropwise to the HEK293T cells. The next day, the medium was exchanged for fresh DMEM plus 20% FBS. After 2 d, target cells were transduced by combining 2.5 ml of viral particle-containing medium containing 8 μg ml shRNA expression and gene downregulation. The lentivirus vector encoding shRNA targeting KRAS (TRCN0000010369) was provided by J. Settleman (Genentech). shRNAs targeting ATG5 (TRCN0000151963 and TRCN0000151474) and ATG7 (TRCN0000007584, TRCN0000007587 and TRCN0000007586) were obtained from the Lenti-shRNA Core Facility (UNC Chapel Hill). Lentiviral particles were generated as described above, except using vector (4 μg), pSPAX2 (3 μg) and pMD2.G (1 μg) plasmid DNAs. After 2 d, target cells were transduced by combining 0.5 ml of viral particle-containing medium with 2 ml of complete medium with polybrene at a final concentration of 8 μg ml -1 with 2 × 10 6 cells per T25 flask. Media were exchanged 8 h later and selection was initiated after 16 h incubation in complete medium. Experiments were typically performed 72-120 h after the initiation of selection.
siRNA treatment of cell lines. siRNA Silencer Select oligonucleotides against scrambled and KRAS sequences were obtained from Thermo Fisher. The siRNA concentration used was 10 nM. Oligonucleotide transfections were performed using RNAiMAX (Life Technologies) according to the manufacturer's instructions. Cells were routinely analyzed 60-72 h after the addition of siRNA. iKRAS cell lines. Cell lines were generated from a doxycycline-inducible Kras G12D-driven mouse model of PDAC (iKRAS) 3 . iKRAS cell lines depend on continued Kras G12D expression for growth and were therefore maintained in doxycycline (1 μg ml -1 ). To silence Kras G12D expression the cells were incubated in growth medium lacking doxycycline for 24 h.
RNA sequencing. For KRAS knockdown studies, a panel of human PDAC cell lines was infected with lentiviral vectors encoding shRNA targeting KRAS or a scrambled control construct for 8-10 h, and then selected for 48-96 h (depending on cell line). For the ERK inhibitor study, cells were seeded at 50% confluence, and the next day were treated with SCH772984 (1 μM) for 24 h. After selection (KRAS studies) or treatment (ERKi studies), cells were washed twice in ice-cold PBS, scraped in ice-cold PBS, collected by centrifugation and flash frozen. Total RNA (50 ng) for the pancreatic cell lines was used to generate whole transcriptome libraries for RNA sequencing using Illumina's TruSeq RNA Sample Prep. Poly(A) mRNA selection was performed using oligo(dT) magnetic beads, and libraries were enriched using the TruSeq PCR Master Mix and primer cocktail. Amplified products were cleaned and quantified using the Agilent Bioanalyzer and Invitrogen Qubit. The clustered flowcell was sequenced on the Illumina HiSeq 2500 for paired 100-bp reads using Illumina's TruSeq SBS Kit V3. Lane level fastq files were appended together if they were sequenced across multiple lanes. These fastq files were then aligned with STAR 2.3.1 to GRCh37.62 using ensembl.74.genes.gtf as GTF files. Transcript abundance was quantified and normalized using Salmon in units of transcripts per million. Clustering was performed using R heatmap.2 package with Euclidean distance and McQuitty clustering method. GSVA was then performed to determine the change and variation in pathway activities on previously published gene signatures. Log transformation was applied, and default parameter settings were followed for RNA-seq data in GSVA.
Immunoblotting. Cells were washed twice with ice-cold PBS, lysed in 1% Triton buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1% Triton) supplemented with phosphatase (Sigma) and protease (Roche) inhibitors, scraped and collected in prechilled tubes. Lysates were then cleared by centrifugation at 15,000g for 10 min at 4 °C, and protein concentration was determined using Bradford assay (Bio-Rad). Standard immunoblotting procedures were followed. Membranes were blocked in 5% BSA diluted in TBS with 0.05% Tween 20 (TBST).
For assessing autophagic flux by immunoblotting, cells were treated with siRNA or ERKi as described in the text and figure legends. Before the collection of samples, cells were treated with bafilomycin A1 (200 nM) for 2 h. Autophagic flux was quantified by immunoblot for LC3B and for densitometric quantification of the LC3B doublet, the ratio of LC3BII to LC3BI is reported.
Quantitative PCR. Total RNA was isolated using a RNeasy kit (Qiagen) and reverse transcription was performed using the High Capacity RNA-to-cDNA kit (Thermo Fisher). Real-time quantitative Taqman PCR was performed on the QuantStudio 6 Flex (Thermo Fisher) with minor groove binder FAM dye-labeled probes against MYC (Hs00153408_m1, Thermo Fisher), SQSTM1 (Hs1061917_g1, Thermo Fisher), GABARAPL1 (Hs00740588_mH, Thermo Fisher), WIPI1 (Hs00924447_m1, Thermo Fisher), BECN1 (Hs01007018_m1, Thermo Fisher) and PRKAA1 (Hs01562315_m1, Thermo Fisher) and endogenous control VIC and TAMRA dye-labeled ACTB (Thermo Fisher).
Immunochemistry and immunofluorescence. All cells were plated in glassbottom dishes (MatTEK Corporation) and imaged on a Zeiss 700 or Zeiss 710 confocal microscope with a 63×, 1.4-numerical aperture objective. Cells expressing mCherry-EGFP-LC3B or labeled with JC-1 were treated as indicated and imaged live. To quantify autophagic flux, the 488-nm and 561-nm laser lines were used to excite mCherry-EGFP-LC3B. Images were acquired in line mode to minimize movement of autophagosomes between acquisition of each channel. Images were analyzed in ImageJ as described previously for the quantification of macropinocytotic vesicles 50 . The ratio of the total fluorescence of mCherry + vesicles to the total fluorescence of EGFP + vesicles is reported as the autophagic index. Cells expressing EGFP-LC3B were treated as indicated, then fixed in 3.7% formaldehyde for 20 min and imaged in 0.001% BSA in PBS. For imaging mitochondria, cells were fixed in 3.7% paraformaldehyde for 15 min at 37 °C. Nonspecific signals were blocked using 0.01% BSA, and cells were permeabilized with 0.1% Triton (15 min). TOMM20 (Santa Cruz Biotechnology) was used to label mitochondria, followed by an Alexa-488 secondary antibody (Invitrogen). DAPI staining (1:10,000) was used to visualize the nucleus. To quantify mitochondrial morphology, cells were imaged and scored blind. More than 50 cells were imaged per cell line and per condition.
To quantify mitophagic flux 49 , the 488-nm and 561-nm laser lines were used to excite cox8-EGFP-mCherry. Images were acquired in line mode to minimize movement of mitochondria between acquisition of each channel. Images were analyzed in ImageJ by first thresholding each channel and finding the area of Articles NAtuRE MEDiCiNE overlap. This overlap region was then used as a mask to analyze the mCherry channel for particles >500 nm 2 in area and >0.15 in roundness to exclusively identify mCherry-only vesicles. The area of mCherry + vesicles was then taken as a proportion of EGFP-mCherry overlap (that is, total mitochondrial area) and represented as a percentage.
Transmission electron microscopy. Transmission electron microscopy samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, then washed in 0.1 M sodium cacodylate buffer and treated with 0.1% Millipore-filtered cacodylate-buffered tannic acid, postfixed with 1% buffered osmium, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated, embedded in LX-112 medium, and polymerized in a 60 °C oven for ~3 d. Ultrathin sections were cut in an Ultracut microtome (Leica), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL) at an accelerating voltage of 80 kV. Digital images were obtained using an AMT Imaging System (Advanced Microscopy Techniques).
Flow cytometry. Apoptosis analyses were performed with the TACS Annexin V-FITC kit (Trevigen) according to the manufacturer's protocol. Briefly, spent culture medium containing detached cells was collected, mixed with trypsinized cells and centrifuged at 300g for 5 min. After washing once in ice-cold 1× PBS, cells were incubated in Annexin V Incubation reagent (1% Annexin V-FITC, 1× propidium iodide solution, in 1× calcium-containing binding buffer) at room temperature for 15 min in the dark before being diluted 1:5 in 1× binding buffer. Cells were analyzed on a BD LSRFortessa flow cytometer, and 30,000 cells were collected and exported with FACSDiva v8.0.1 and analyzed with Cytobank. First, for a side scatter area (SSC-A) (y) versus forward scatter area (FSC-A) (x) dot plot, a 'cells' gate was used to exclude small and large debris that fell in the bottom right corner or off-scale on either axis. Cells were analyzed for apoptosis in a propidium idodide area (PI-A) (y) versus fluorescein isothiocyanate area (FITC-A) (x) dot plot and a quadrant gate was established around the healthy population of DMSO control cells (PI-A negative, FITC-A negative). To assess mitochondrial mass, cells were plated and treated the next day as indicated. After 24 h of treatment, cells were labeled with MitoTracker Green FM (50 nM, Thermo Fisher Scientific) in the presence of drug for 30 min according to the manufacturer's instructions. Cells were subsequently washed with PBS, harvested with trypsin and washed an additional time with PBS before being resuspended in Tyrodes solution (20 mM HEPES, 135 mM NaCl, 1.8 mM CaCl 2 , 2 mM MgCl 2 , 5.6 mM glucose, pH 7.4) supplemented with 1% BSA (Tyrodes/BSA) and analyzed on a BD LSRFortessa flow cytometer. After separating live cells from debris and dead cells with a 'cells' gate in an SSC-A (y) versus FSC-A (x) dot plot, doublets were excluded with a forward scatter height (FSC-H) (y) vs FSC-A (x) dot plot and 30,000 singlet cells were analyzed for FITC staining on a histogram. Emission wavelengths were monitored with a 595-nm longpass filter and at 610 nm with a 20 nm bandpass (610/20) filter from a 561-nm laser line for PI, and with a 505-nm longpass filter and at 530 nm with a 30 nm bandpass (530/30) filter from a 488-nm laser line for FITC. Data were collected and exported with FACSDiva v8.0.1 and analyzed with FCS Express 6.
To assess mitochondrial potential in human PDAC cell lines, cells were plated and treated as described above, washed with PBS, harvested with trypsin, centrifuged at 300g for 5 min and resuspended in DMEM plus 10% FBS containing JC-1 mitochondrial dye (2 μM, Thermo Fisher Scientific) with inhibitor for 30 min at 37 °C. For cells treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP), cells were first incubated with 50 μM CCCP for 5 min at 37 °C before JC-1 was added. After incubation, cells were washed with PBS, resuspended in Tyrodes/BSA with drug and immediately analyzed on a BD LSRFortessa flow cytometer. Data were collected by monitoring emission wavelengths at 610 nm with a 20 nm bandpass (610/20) and a 595-nm longpass filter and at 530 nm with a 30 nm bandpass (530/30) and a 505-nm longpass filter with the 488-nm laser line for excitation. Data were exported with FACSDiva v8.0.1 and analyzed with FCS express 6. Cells were discriminated as described above, and singlet populations were gated using a dot plot of FCS-H (y) vs FCS-A (x). Compensation was performed manually using a dot plot of 610-nm emission (y) and 530-nm emission (x) of the control samples incubated with CCCP to give a homogenous population on the x-axis. Overlays were generated by plotting the signal from the 610-nm emission (representing JC-1 aggregates) versus 530-nm emission (representing JC-1 monomers) of the compensated data sets. Histograms represent the median JC-1 aggregate/monomer ratio from overlays.
To assess mitochondrial potential in iKRAS mouse cells, cells were seeded in 12-well plates. On the second day, cells were washed with PBS twice and cultured with or without doxycycline. After 24 h, tetramethyl rhodamine, ethyl ester (TMRE) was added to the cells in medium to a final concentration of 200 nM and incubated at 37 °C for 20 min. Cells were then harvested with trypsin and washed with PBS, and TMRE staining was analyzed on a Beckman Gallios Flow Cytometer. After excluding dead cells with DAPI staining, singlets gated with a FCS-H (y) vs FCS-A (x) dot plot were analyzed for TMRE staining on a histogram. Data were collected and analyzed with Kaluza Analysis 1.5a. The median of the TMRE signal was normalized to doxycycline ON (that is, KRAS expression). The mitochondrial uncoupler FCCP (20 μM) was added to doxycycline ON cells for 30 min before TMRE staining and then processed as described above as a positive control.
Sample preparation and reverse-phase protein microarray. Six-well plates were lysed in buffer prepared and processed as we described previously 51 . Protein concentration was estimated using the Coomassie Protein Assay Reagent kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Cell lysates were diluted to 0.5 mg ml -1 in 2× Tris-glycine SDS Sample buffer (Life Technologies) supplemented with 5% β-mercaptoethanol and boiled for 8 min. Samples were stored at −20 °C until arrayed. Cell lysates and internal experimental controls were immobilized onto nitrocellulose-coated glass slides (Grace Bio-Labs) and printed in technical replicates (n = 3) using an Aushon 2470 automated system (Aushon BioSystems) 52 . Protein concentration in each sample was quantified in selected arrays using a Sypro Ruby Protein Blot Stain (Molecular Probes) protocol according to the manufacturer's instructions. The remaining arrays were pretreated with Reblot Antibody Stripping solution (Chemicon) for 15 min at room temperature, followed by two washes with PBS, and incubated for 5 h in I-block (Tropix) before antibody staining 51 . Using an automated system (DakoCytomation), arrays were incubated with 3% hydrogen peroxide and blocked in biotin (DakoCytomation) and an additional serum-free protein block (DakoCytomation) to reduce nonspecific binding of endogenous proteins. Each array was probed for 30 min with one antibody targeting the protein of interest. Arrays were probed with ~160 antibodies targeting proteins involved in signaling networks that regulate cell growth, survival and metabolism (See Supplementary Table 2 for complete list). Antibodies were validated for their use on the RPPA platform as described 53 . Biotinylated anti-rabbit (Vector Laboratories) or anti-mouse secondary antibody (DakoCytomation) and a commercially available tyramide-based avidin-biotin amplification system (Catalyzed Signal Amplification System, DakoCytomation) were used for signal amplification. IRDye 680RD streptavidin (LI-COR Biosciences) was used as a fluorescent detection system. Sypro Ruby-and antibody-stained slides were scanned on a laser scanner (TECAN). Images were analyzed using commercially available software (MicroVigene Version 5.1.0.0, Vigenetech) as described 54 . Intensity levels of treated and untreated (DMSO control) cells were compared under a null hypothesis stating that there was not a difference between the means of the two groups. Quantilequantile plots were used to assess sample distribution and normality for each of the measured analyses. Based on sample distribution, a two-sided parametric t-test or a nonparametric Wilcoxon rank-sum test was used to compare the population means of treated and untreated (DMSO control) cells 54 . Statistical analysis was performed using the software package R; P ≤ 0.05 was considered statistically significant. Spearman's nonparametric correlation analysis was performed for an experimental set of signaling proteins among all 24-h samples using the Hmisc package (v4.1-1) in R 3.4.3. Two-sided t-testing was used to assess the statistical significance of correlation coefficients. Unsupervised hierarchical clustering with the gplots package (v3.0.1) was used to generate heatmaps.
Oxygen consumption. Human PDAC cell lines were harvested and seeded into XF96 cell culture microplates (Seahorse Bioscience). To measure oxygen consumption rate (OCR) after inhibitor treatment, cells were treated for 24 h with ERKi (SCH772984, 1 μM). On the day of the experiment, culture medium was exchanged for base assay medium containing 25 mM glucose, 1 mM glutamine and 1 mM sodium pyruvate; cells remained in the presence of their respective treatment conditions. Oligomycin, FCCP, antimycin and rotenone (XF Cell Mito Stress Test Kit, Seahorse Bioscience) were injected sequentially. Experiments were run using an XF96 analyzer and raw data were normalized to cell number, evaluated by live cell counting and imaged with a SpectraMax MiniMax 300 Imaging Cytometer (Molecular Devices). To measure OCR after KRAS suppression, cells were treated with siRNA targeting KRAS as described above. After 48 h of knockdown, cells were harvested, counted and seeded into XF96 cell culture microplates as described above. The next day, the XF Cell Mito Stress Test Kit was used and data were normalized as described above.
Metabolomics. For the [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose metabolic flux assay, cells were either treated with SCH772984 or transfected with siRNA targeting KRAS as described. Upon inhibitor treatment or after genetic suppression of KRAS, culture medium was exchanged with fresh DMEM containing 13 C-labeled glucose and a 24-h time course experiment was performed during which media samples and cell extracts were collected at the indicated time points. Cells were rinsed with PBS and extracted in 100% methanol on ice, then vortexed and diluted to 80% methanol before being frozen at −80 °C overnight. Cell debris was removed by centrifugation at 15,000 r.p.m. for 5 min, and then extracts were dried in a speed vacuum. Dried extract was resuspended in 60 μl of 50:50 acetonitrile/water and vortexed, and 10 μl was used for LC-MS analysis. The LC portion used a HILIC column (Venusil HILIC Column, 3 μm, 100 Å, 2.1 × 100 mm, Agela Technologies) attached to an ABSciex 5600 TripleTOF mass spectrometer in positive mode as described 37 . All NMR spectra were processed using ACD/1D NMR Manager software (version 12.0; ACD/Labs). Isotopologues were determined from the mass spectral data as described 37 , using the software Isocor
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For metabolite labeling assay by gas chromatography-MS (GC-MS), dried residues were resuspended in 25 μl of methoxylamine hydrochloride (2% (w/v) in pyridine) and incubated at 40 °C for 90 min. After brief centrifugation, 35 μl of N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) plus 1% tert-Butyldimethylchlorosilane (TBDMS) was added, and the samples were incubated at 60 °C for 30 min. The derivatized samples were centrifuged for 5 min at 20,000g, and the supernatants were transferred to GC vials for GC-MS analysis. The injection volume was 1 μl, and samples were injected in split or splitless mode depending on analyte of interest. GC oven temperature was held at 80 °C for 2 min, increased to 280°C at a rate of 7 °C per min, and held at 280 °C for a total run time of 40 min. GC-MS analysis was performed on an Agilent 7890B GC system equipped with a HP-5MS capillary column (30 m, 0.25-mm internal diameter, 0.25-µm phase thickness; Agilent J&W Scientific), connected to an Agilent 5977 A GC/MS Spectrometer operating under ionization by electron impact at 70 eV. Helium flow was maintained at 1 ml min -1 . The source temperature was maintained at 230 °C, the MS quad temperature at 150 °C, the interface temperature at 280 °C and the inlet temperature at 250 °C. Mass spectra were recorded in scan mode from m/z of 50 to 700. Measured mass isotopomer distributions, expressed as mol percentage, were corrected for natural enrichment 56, 57 . For isotopologue analysis of 13 C-labeled metabolites, glucose consumption and glycolytic flux of glucose to lactate were determined using 1 H NMR spectroscopy as described 37 . To determine the TCA cycle flux, the time courses of M+1 and M+2 glutamate, representing the first and second turns of the TCA cycle, respectively, as described 37 , were plotted and fit with an exponential using Prism software (v. 5.0).
For one-dimensional LC-MS/MS-based polar metabolomics experiments, cells were cultured in DMEM containing 10% FBS until they reached 70% confluence. Media were exchanged with fresh DMEM containing either DMSO (vehicle) or SCH772984 (1 μM) for 22 h, then exchanged for fresh medium for another 2 h. Cells were rinsed with PBS and snap-frozen on dry ice. Cell extracts were prepared in 80% methanol on dry ice and incubated on dry ice for 30 min, and cell debris was removed. Extracts were lyophilized and subjected to mass spectrometry analysis according to published methodology 58, 59 . Metabolite levels were normalized to the protein content of cell lysates obtained from cells treated with similar conditions. Drug response testing. Cells (1,000-2,500 per well depending on cell line) were seeded in 96-well plates and incubated for 24 h before addition of drug. For synergy studies with chloroquine, cells were treated with SCH772984 (19.5 nM to 10 μM), BVD-523 (19.5 nM to 10 μM) or binimetinib (4.87 nM to 2.5 μM) and chloroquine (0.78 μM to 12.5 μM) in a matrix. Cells were incubated at 37˚C for 72 h or 5 d before proliferation was quantified. For experiments involving other autophagy inhibitors, cells were treated with SCH772984 (19.5 nM to 10 μM) either alone or in combination with a constant amount of Spautin-1 (targeting Vps34; 1.25 μM), SBI-0206965 (targeting ULK1; 2 μM) or MRT68921 (targeting ULK1/2; 500 nM) (Xcessbio). DMSO was held constant at 5 nM. Cells were incubated at 37 ˚C for 5 d. Proliferation was quantified using a SpectraMax i3x multimode detection platform (Molecular Devices) by live-cell counting after labeling with calcein AM (500 nM, 15 min) (Invitrogen). Calcein AM labeling was used solely to mark cells (above background) for counting, thus total fluorescence was not used as a measure of viability. Alternatively, in for some assays, proliferation was assessed by incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) for 3 h before cell lysis and quantification of absorbance at 550 nm. Parental ATG5 and ATG7 knockdown cells were generated as described above, plated and treated with SCH772984 (19.5 nM to 10 μM) . At that time, samples were also collected for immunoblotting to confirm reduction in ATG5/7 proteins. Viability was assessed by live cell counting of calcein AM-labeled cells after 72 h of treatment. Percentage viability was calculated by normalizing treated values to vehicle-control (DMSO-treated) samples. Four-parameter drug response curves were generated with GraphPad Prism version 7.03. Combination indices were calculated with CompuSyn software.
For anchorage-dependent colony-formation assays, cells were seeded at a density of 750-2,500 cells per well depending on cell line. After 24 h, cells were treated with indicated concentrations of ERKi (SC772984 or BVD-523) and chloroquine. The cells were cultured until quantifiable colonies appeared in the DMSO control wells (10-14 d) . Cells were stained with crystal violet and the total area covered by stain was quantified in Fiji.
For anchorage independent growth assays, cells were seeded into 100 μl of growth-factor-reduced Matrigel (Corning) domes in the centers of individual wells of a 24-well plate at a concentration of 5,000 cells per dome. The next day, wells were drugged as indicated. Matrix-embedded spheroids were grown for 2 weeks, and drugs were replenished every 4 d. To quantify proliferation, domes were incubated with AlamarBlue reagent (1:10 dilution of stock, Invitrogen) for 8-16 h. Media samples were transferred to a 96-well plate and fluorescence (560-nm excitation, 590-nm emission) was read using a SpectraMax i3x multimode detection platform (Molecular Devices). For organoid viability assays, organoids were dissociated and 3,000 single cells per well were seeded in 150 µl of 10% growth-factor-reduced Matrigel (Corning) and 90% human organoid feeding medium plus 10.5 µM Y27632 (Selleckchem) into poly(2-hydroxyethyl methacrylate)-coated (Sigma) 96-well, clear flat-bottom plates (Corning, 3903).
On the second day after seeding organoids were drugged with SCH772984 (78.1 nM to 2.5 μM) and chloroquine (1.56-12.5 μM) , and chloroquine was replenished every 4 d. At 10 d after drugging, organoids were imaged with the Molecular Devices SpectraMax i3x MiniMax 300 imaging cytometer. After image acquisition, organoid viability was accessed with Cell Titer Glo 3D Cell Viability assay (Promega) according to the manufacturer's protocol on the SpectraMax i3x plate reader. Bliss independence scores were calculated and heatmaps were generated using R 3.4.3. Combination indices were calculated using Compusyn software.
Subject-derived xenotransplantation models. PDX models were used to assess the effect of the ERK1/ERK2i plus hydroxychloroquine inhibitor combination on tumor growth. Subjects consented to the collection of tissue for the development of PDX models under approved Institutional Review Board protocol of the University of Arizona. NOD-SCID IL2Rγ null (NSG) mice were purchased from The Jackson Laboratory and experiments were performed at the University of Arizona. All mice were maintained in a specific pathogen-free facility and all animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committees of the University of Arizona. All of the PDX models were established by direct engraftment of pancreatic cancer tissue fragments from subjects undergoing surgical resection into NSG mice, expanded and viably frozen at low passage for future use. All of the PDX models deployed were developed from subjects who were therapy naïve. To develop treatment cohorts, frozen PDX tumor fragments were thawed, implanted into recipient mice and expanded by passaging in mouse without exposing tumor fragments to in vitro conditions. PDX were passaged in NSG mice to develop treatment cohorts. Mice were randomized to treatment arms comprised of approximately equal numbers of male and female mice when tumors reached 100-200 mm 3 . All treatment arms contained four or more mice to support the statistical analysis performed. SCH772984 was delivered at 50 mg kg 
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Binary sequence alignment/map (BAM) files of RNA-seq data from KRAS knockdown and ERK inhibitor treatment studies are available from the European Bioinformatics Institute European Nucleotide Archive database (http://www.ebi. ac.uk/ena/) with accession numbers PRJEB25797 and PRJEB25806, respectively. For the KRAS knockdown study, the sample accession numbers are ERS2363485-ERS2363504. For the ERK inhibitor treatment study, the sample accession numbers are ERS2367000-ERS2367034. All other data sets generated for the current study are available from the corresponding author upon request. 
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
Confocal images were collected on a Zeiss 700 or 710 Microscope using ZEN Microscope and Imaging Software. Digital images of TEM were obtained using an AMT Imaging System. For RNA sequencing fastq files were aligned with STAR 2.3.1 to GRCh37.62 using ensembl.74.genes.gtf as GTF file. Real time quantitative Taqman PCR was performed on the QuantStudio 6 Flex. Flow cytometry samples were analyzed on a BD LSRFortessa flow cytometer and exported with FACSDiva v8.0.1, or on a Beckman Gallios Flow Cytometer with Kaluza acquisition software. Oxygen consumption was measured using a Seahorse Bioanalyzer running Wave 2.3.0 software. for GC/MS raw data was collected using Agilent MassHunter data acquisition software. NMR spectrometry was acquired using TopSpin from the Bruker Corporation, Billerica, and LC-MS was acquired using Analyst Software from AB Sciex. For LC-MS/MS studies, MassLynx (Waters) was used for data acquisition. Dose response data was collected using a SpectraMax i3x plate reader as well as a SpectraMax Minimax 300 Imaging Cytometer using SoftMaz Pro 7 software. Immunoblots were imaged using a Biorad ChemiDox MP Imaging System running Image Lab 6.0. RPPA samples were prepared using an Aushon 2470 and a DakoCytomation automated system and stained slides were scanned on a TECAN laser scanner.
Data analysis
Quantitiation of confocal images and densitometry of immunoblots was performed using Fiji for Mac OS X (available for free download at https://fiji.sc/#download). Analysis was done using only packaged scripts, no new code was generated. For RNA sequencing transcript abundance was quantified and normalized using Salmon in the unit of transcripts per million (TPM). Clustering was performed using R heatmap.2 package with Euclidean Distance and McQuitty clustering method. Gene set variation analysis (GSVA) was then performed to determine the change and variation in pathway activities on previously published gene signatures. Log transformation was applied, and default parameter settings were followed for RNA-Seq data in GSVA. Flow data was analyzed with Cytobank, FCS Express 6, or Kaluza software, as described in the methods, using packaged functions. Oxygen consumption, Spare Capacity and ATP Production were
March 2018
calculated using the Agilent Seahorse XF Mito Stress Test Report Generator. Spearman's non parametric correlation analysis of RPPA data was performed using the Hmisc package (v4.1-1) in R3.4.3. Unsupervised hierarchical clustering with the gplots package (v3.0.1) was used to generate heatmaps (Figure 3a, Figure 5 d-e, and Extended Data Figure 3a) . All code will be made available in the Der Lab GitHub repository. All NMR Spectra were processed and data obtained using ACD Labs NMR Processor software. LC-MS data was extracted using Makerview from AB Sciex LP. Fraction enrichments of the isotopologues were obtained using IsoCor. For GC/MS data was processed using Agilent MassHunter quantitation software. For LC-MS/MS TargetLynx (Waters) was used for the integration of peaks. RPPA images were analyzed using commercially available software from Vigenetech, MicroVigene Version 5.1.0.0. CI values were calculated using Compusyn (available for free download at http://www.combosyn.com/register.html). All statistical analysis was done using GraphPad Prism v 5.0 and v 7.03.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
For RNA sequencing data: Binary sequence alignment/map (BAM) files of RNA-seq data from KRAS knock down and ERK inhibitor treatment studies are available from the EMBL-EBI European Nucleotide Archive (ENA) database -http://www.ebi.ac.uk/ena/ with accession number PRJEB25797 and PRJEB25806, respectively. The data is accessible via http:// www.ebi.ac.uk/ena/data/view/PRJEB25797 and http://www.ebi.ac.uk/ena/data/view/PRJEB25806. For the KRAS knock down study, the sample accession numbers are ERS2363485-ERS2363504. For the ERK inhibitor treatment study, the sample accession numbers are ERS2367000-ERS2367034. The figures that were generated from this data include: Figure For RPPA data analysis:
All unique code generated to analyze RPPA data will be deposited into the following github: https://github.com/derlab/Bryant_Nature_2018. This code was used to generate Extended data Figure 3c . 
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Authentication All cell lines were STR profiled for authenticity.
Mycoplasma contamination
All cell lines were routinely tested for mycoplasma. Cell lines that tested positive were immediately discarded and all data (if any) was not used in the analyses.
Commonly misidentified lines (See ICLAC register) None used.
Research animals
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Animals/animal-derived materials NSG mice were purchased from The Jackson Laboratory and experiments were performed at the University of Arizona. All mice were maintained in a specific pathogen-free facility and all animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committees of the University of Arizona.
Mice were 6-8 weeks old at the time of PDAC PDX tumor implantation. A mix of 50% male and 50% female mice were used. PDAC PDX models were used to assess the effect of the ERK1/2i + HCQ inhibitor combination on tumor growth. PDX were passaged in NSG mice to develop treatment cohorts. Mice were randomized to treatment arms comprised of approximately equal numbers of male and female mice when tumors reached 100-200 mm3. ERK1/2i SCH772984 was delivered at 50 mg/kg 6 days per week by intraperitoneal injection (IP). HCQ was delivered at 60 mg/kg 6 days per week via IP injection. Tumor volumes were measured by digital calipers every 48 h. The average tumor volume and standard error of the mean were graphed. Mice were sacrificed when tumors reached >1000 cm or at the end of 21 days of treatment.
Method-specific reporting n/a Involved in the study The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Apoptosis analyses were performed with the TACS® Annexin V-FITC Kit (Trevigen, Inc.) following the manufacturer's protocol. Briefly, spent culture medium containing detached cells was collected, mixed with trypsinized cells and centrifuged at 300×g for 5 min. After washing once in ice-cold 1X PBS, cells were incubated in Annexin V Incubation Reagent (1% Annexin V-FITC, 1X propidium iodide solution, in 1X calcium-containing binding buffer) at RT for 15 min in the dark before diluting 1:5 in 1X binding buffer.
To assess mitochondrial mass, cells were plated and treated the next day as indicated. Following 24 h of treatment, cells were labeled with MitoTracker Green FM (50 nM, Thermo Fisher Scientific) in the presence of drug for 30 min following manufacturer's instructions. Cells were subsequently washed with PBS, harvested with trypsin, and washed an additional time with PBS before being resuspended in Tyrodes/BSA (20 mM HEPES, 135 mM NaCl, 1.8 mM CaCl2, 2 mM MgCl2, 5.6 mM glucose, 1 mg/ml BSA, pH 7.4) and analyzed.
To assess mitochondrial potential in human PDAC cell lines, cells were plated and treated as described above, washed with PBS, harvested with trypsin, centrifuged at 300xg for 5 min, and resuspended in DMEM + 10% FBS containing JC-1 mitochondrial dye (2 uM, Thermo Fisher Scientific) with inhibitor for 30 min at 37°C. For cells treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP), cells were first incubated with 50 uM CCCP 5 min at 37°C before JC-1 was added. Following incubation, cells were washed with PBS, resuspended in Tyrodes/BSA with drug and immediately analyzed.
To assess mitochondrial potential in iKRAS mouse cells, cells were seeded in 12-well plates. On the second day, cells were washed with PBS twice and cultured with or without doxycycline (Dox). After 24 h, tetramethyl rhodamine, ethyl ester (TMRE) was added to the cells in media to a final concentration of 200 nM and incubated at 37ºC for 20 min. Cells were then harvested with trypsin, washed with PBS and TMRE staining was analyzed. The mitochondrial uncoupler FCCP (20 M) was added to Dox ON cells for 30 min prior to TMRE staining and then processed as described above as a positive control.
Instrument
For apoptosis studies and mitochondrial mass, and mitochondrial potential studies in human cell lines, cells were analyzed on a
